Drug Interaction Between Clopidogrel and Ranitidine or Omeprazole in Stable Coronary Artery Disease: A Double-Blind, Double Dummy, Randomized Study.
Furtado, Remo Holanda de Mendonça; Giugliano, Robert Patrick; Strunz, Celia Maria Cassaro; Filho, Cyrillo Cavalheiro; Ramires, José Antonio Franchini; Filho, Roberto Kalil; Neto, Pedro Alves Lemos; Pereira, Alexandre Costa; Rocha, Tânia Rúbia; Freire, Beatriz Tonon; D'Amico, Elbio Antonio; Nicolau, José Carlos.
Am J Cardiovasc Drugs
; 16(4): 275-84, 2016 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-27289472
Variability of platelet response to clopidogrel is not related to adverse cardiovascular events in patients with stable coronary artery disease undergoing percutaneous coronary intervention.
Omeprazole, pantoprazole, and CYP2C19 effects on clopidogrel pharmacokinetic-pharmacodynamic relationships in stable coronary artery disease patients.
Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events.
Platelet factor XIIIa release during platelet aggregation and plasma clot strength measured by thrombelastography in patients with coronary artery disease treated with clopidogrel.
Combination antiplatelet treatment in coronary artery disease patients: A necessary evil or an overzealous practice?
How I use laboratory monitoring of antiplatelet therapy.
[Platelet Metabolism in Clopidogrel Resistant and Sensitive Patients With Ischemic Heart Disease].
Dual antiplatelet therapy for coronary artery disease.
[Impact of CYP2C19 genotype and platelet function on clinical outcome in coronary atherosclerotic heart diseases patients received clopidogrel post percutaneous coronary intervention].
Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease.